Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Characteristics of frontotemporal dementia
- Genes involved in frontotemporal dementia
- Pathology of frontotemporal dementia (FTD)
- FTDP-17: 3R and 4R-tauopathies
- FTD-TDP subtypes
- FTLD-TDP type A
- FTD-TDP type B
- FTD-TDP types C and D
- MAPT as the gene for FTD with tangles
- The microtubule associated protein tau
- Mutations affecting tau protein in FTD
- Tau exon 10 3’ splice site mutations
- PGRN mutations as a cause for FTD
- FTD is caused by truncating GRN mutations
- A major locus for FTD & ALS on chromosome 9
- ALS-FTD locus shared by different families
- The position of the C9orf72 expansion
- C9orf72 expansions
- A hexanucleotide repeat expansion in C9orf72
- Mechanisms of C9orf72
- Chromosome 3 dementia
- Chromosome 3 dementia - family tree
- FTD & chromatin-modifying protein 2B (CHMP2B)
- Making sense of these genes (1)
- Making sense of these genes (2)
Topics Covered
- Overall characteristics of FTD
- Genes involved in frontotemporal dementia
- Pathology of frontotemporal dementia
- FTDP-17: 3R and 4R-tauopathies
- FTLD-TDP subtypes
- MAPT as the gene for FTD with tangles
- The microtubule associated protein tau
- Mutations affecting tau protein in FTD
- PGRN mutations as a cause for FTD
- A major locus for FTD and ALS on chromosome 9
- Chromosome 3 dementia
- Making sense of these genes
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Hardy, J. (2014, July 1). The genetics of frontotemporal dementia [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 27, 2024, from https://doi.org/10.69645/VAXT7849.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. John Hardy, Consultant: Eisai Speaker's Bureau: Eli Lily Grant/Research Support (Principal Investiqator): MRC/Wellcome Trust
A selection of talks on Genetics & Epigenetics
Transcript
Please wait while the transcript is being prepared...
0:00
Hello.
My name's John Hardy.
I work at the Institute of Neurology
at University College London.
What I'm going to talk
to you today about
is the genetics of
frontotemporal dementia.
This is either the second or the
third most common form of dementia
after Alzheimer's disease, and
afflicting about the same number
of people who have
dementia with Lewy bodies.
It's a devastating disease, as
I'll explain later, and really
a major public health
problem and, of course,
social problem for those people
who are afflicted with the disease.
0:38
The characteristics of
frontotemporal dementia
are that the frontal and
temporal lobes of the brain
are affected and show gross atrophy.
It's responsible for about
10% of all dementias,
and depending on the survey, affects
somewhere of the order of 3 to 15
every 100,000 individuals.
The reason there is
this type of variability
is because sometimes the diagnosis
is rather difficult to make
and because it can sometimes
resemble Alzheimer's disease.
Unless there is
neuropathological confirmation,
then prevalence rates can vary based
upon the diagnostic criteria which
are used.
The onset age for the
disease is typically
in the late 50s or early 60s of age.
I do know of cases where the
onset age is from the 30s.
And of course, it can afflict
people in their 70s and 80s.
But the typical ages of onset are,
as I say, in the 50s and the 60s.
High proportion, about a quarter
of the cases, are familial.
That means usually that people
in the familial category
have one of their parents
who have had the disease.
And of course, the grandparent
on that side of the family
can also have been afflicted.
So sometimes, you
can see the disease
traveling down through
many generations.
It's a very variable disease in
terms of its clinical presentation.
Some people have language problems
very early in the disease.
They have difficulty speaking.
They become what is known as
aphasic, and they can't find words.
Other individuals have
personality changes
very early in the disease process.
And they can become either
apathetic or rather disinhibited.
A very frequent
complaint of caregivers
is that their loved one seems as
if they're drunk in their behavior.
They either become very
quiet and almost mute,
or they become very
inappropriate in social settings.
In agreement with this
clinical variability,
there is actually a lot of
pathological variability.
So I've described how the disease
is characterized by atrophy
of the frontal lobes or the
temporal lobes of the brain.
But the histopathology-- that means
the pathology in the brain cells--
is also variable.
And to some extent,
though not perfectly,
this pathological variability fits
with what I'm going to tell you
about the genetic heterogeneity
and also fits to some extent
with the clinical
heterogeneity, as well.